Abstract Search Browse Program and Abstracts Schedule-at-a-Glance Conference Mission & Sponsors Program Committee Contact Us


View All Abstracts for Session 42



234   Development of a Controlled-Release HIV Vaccine Adjuvant  

T. Castor* and P. O. Ilyinskii
Aphios Corp., Woburn, MA, USA


We have developed an enhanced controlled-release technology for nanoencapsulating potent HIV antigens in polymer nanospheres to protect and sustain the release of HIV viral antigens. We are doing so by utilizing SuperFluids, which are gases that exhibit enhanced solvation, penetration, and expansive properties when compressed. Vaccination remains the most cost-effective tool for the control and prevention of infectious diseases. However, multiple inoculations are often required to achieve desirable protection even with potent HIV antigens. Controlled-release technology will be quite effective in improving the therapeutic efficacy of such vaccines. The use of SuperFluids reduces exposure of the HIV antigens to potentially denaturing organic solvents such as methylene chloride and ethyl acetate and improves the stability of protein antigens in the body at ambient temperature for long periods, thereby enhancing the capability of nanoencapsulated HIV vaccine antigens to induce the production of protective and neutralizing antibodies. This controlled-release vaccine delivery technology will have the capability to deliver different types and combinations of HIV vaccine candidates including whole inactivated HIV virus particles and/or HIV subunit protein antigens. Our nanoencapsulation technology will reduce cost by eliminating unnecessary processing steps while improving the manufacturing environment. Unlike currently available technologies, this technology is quite inexpensive, amenable to large-scale processing, and quite portable. The controlled or timed release of HIV antigens through the use of this technology would minimize or obviate the need for repeat visits to clinics for booster inoculations to generate protective immunity. This would be a tremendous benefit for any vaccine employed for first-world as well as third-world countries.

Contact Author about this Abstract